New Antibiotics Hailed as a 'Major Shift' in Treating Drug-Resistant Gonorrhoea

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.

An International Health Concern

Cases of gonorrhoea are increasing globally, with data suggesting over 82 million new cases each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is additionally indicated for urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Data and Global Access

According to data released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an comparable level with the current standard treatment, which involves a dual-drug approach. The research included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed optimism. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.